Eiger Biopharmaceuticals (NASDAQ:EIGR) announced its quarterly earnings data on Monday. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.09), Bloomberg Earnings reports.
Shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) traded up $0.20 on Tuesday, reaching $9.15. The company’s stock had a trading volume of 30,982 shares, compared to its average volume of 172,973. Eiger Biopharmaceuticals has a fifty-two week low of $6.10 and a fifty-two week high of $16.20. The company has a current ratio of 5.78, a quick ratio of 5.78 and a debt-to-equity ratio of 1.19. The firm has a market cap of $102.63, a PE ratio of -1.70 and a beta of 1.70.
Several analysts recently weighed in on EIGR shares. Oppenheimer set a $26.00 price objective on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Ladenburg Thalmann Financial Services started coverage on Eiger Biopharmaceuticals in a research report on Wednesday, January 3rd. They set a “buy” rating and a $32.00 price objective for the company. Zacks Investment Research upgraded Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Tuesday, January 9th. Piper Jaffray Companies restated an “overweight” rating and set a $17.00 price objective (down from $35.00) on shares of Eiger Biopharmaceuticals in a research report on Tuesday, January 16th. Finally, ValuEngine upgraded Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Eiger Biopharmaceuticals has an average rating of “Buy” and a consensus price target of $27.25.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.